Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR. 18.

被引：0
|
作者：
Leighl, NB
Shepherd, F
Paz-Ares, L
Douillard, JY
Peschel, C
Arnold, A
Tu, D
Galbraith, S
Hann, K
Seymour, L
机构：
[1] Natl Canc Inst Canada, Kingston, ON, Canada
[2] Bristol Myers Squibb, Wallingford, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7038
引用
收藏
页码：626S / 626S
页数：1
相关论文
共 50 条
  • [21] Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer
    Okamoto, I
    Moriyama, E
    Fujii, S
    Kishi, H
    Nomura, M
    Goto, E
    Kiyofuji, C
    Imamura, F
    Mori, T
    Matsumoto, M
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (04) : 188 - 194
  • [22] Randomized, open-label phase 2 study of safety and efficacy of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC)
    Blumenschein, Jr George
    Kabbinavar, Fairooz
    Menon, Hari
    Mok, Tony S. K.
    Stephenson, Joe J.
    Beck, J. Thaddeus
    Lakshmaiah, Kuntegowdanahalli
    Reckamp, Karen
    Hei Yong-jiang
    Kracht, Karolyn
    Sikorski, Robert
    Schwartzberg, Leee
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S354 - S355
  • [23] Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC)
    Belani, C. P.
    Ramalingam, S.
    Schreeder, M.
    Steis, R.
    Guidice, R.
    Marshland, T.
    Butler, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC)
    Giorgio, CG
    Pappalardo, A
    Russo, A
    Giuffrida, D
    Santini, D
    Petralia, G
    Castorina, S
    Nunzio, R
    Failla, G
    Bordonaro, R
    LUNG CANCER, 2006, 51 (03) : 357 - 362
  • [25] Carboplatin plus gemcitabine followed by weekly paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC): A phase II study
    Tjan-Heijnen, V
    Timmer-Bonte, J
    van der Drift, M
    van Leeuwen, F
    de Boo, T
    Wagenaar, M
    van Die, L
    Bussink, J
    LUNG CANCER, 2005, 49 : S272 - S272
  • [26] Quality of life (QOL) outcomes with cediranib/placebo in combination with carboplatin/paclitaxel (CP) in advanced non-small cell lung cancer (ANSCLC): results from NCIC CTG BR.24
    Lee, Christopher W.
    Ding Keyue
    Le Maitre, Aurelie
    Han, Lei
    Laurie, Scott A.
    Goss, Glen
    Shepherd, Frances A.
    Arnold, Andrew
    Frymire, Eliot
    Seymour, Lesley
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S288 - S288
  • [27] A phase II study of carboplatin (C) and weekly paclitaxel (P) with a selective cyclooxygenase-2 (COX-2) inhibitor, meloxicam, in advanced non-small cell lung cancer (NSCLC)
    Suzuki, R.
    Yamamoto, M.
    Saka, H.
    Taniguchi, H.
    Shindo, J.
    Tanikawa, Y.
    Nomura, S.
    Oishi, T.
    Hasegawa, Y.
    Shimokata, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Randomized, open label, phase III trail of figitumamab in combination with pacilitaxel and carboplatin versus paclitaxel and carboplatin in patients wiht non-small cell lung cancer (NSCLC)
    Jassem, J.
    Langer, C. J.
    Karp, D. D.
    Mok, T.
    Benner, R. J.
    Green, S. J.
    Park, K.
    Novello, S.
    Strausz, J.
    Gualberto, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Phase I/II trial of paclitaxel (P), carboplatin (C), and irinotecan (CPT-11) in advanced, metastatic non-small cell lung cancer (NSCLC)
    Socinski, MA
    Miller, LL
    Sandler, AB
    Israel, VK
    Hanover, CK
    Locker, PL
    Elfring, GL
    Natale, RB
    SEMINARS IN ONCOLOGY, 1999, 26 (06) : 23 - 23
  • [30] A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC).
    Blumenschein, GR
    Khuri, F
    Gatzemeier, U
    Miller, WH
    von Pawel, J
    Rigas, JR
    Herbst, RS
    Dziewanowska, Z
    Negro-Vilar, A
    Mabry, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1094S - 1094S
12345